Skip to main content
. 2014 May 7;192(12):5821–5829. doi: 10.4049/jimmunol.1400404

FIGURE 2.

FIGURE 2.

IL-2/αCD40 induces the Fas-dependent loss of Tregs and MDSCs in the tumor microenvironment. Renca tumor-bearing mice were treated with VC or IL-2/αCD40. Black bars denote mice that were treated with either blocking Ab against Fas ligand or isotype-matched control Ab. White bars indicate VC- or IL-2/αCD40–treated MRL-Fas(lpr) mice. On day 22, mice were euthanized, and the spleens and primary tumors were harvested. The total number of (A) Tregs and (B) MDSCs in the spleen was determined by multiplying the number of CD45+ leukocytes by the percentage in each sample. The number of tumor-associated (C) Tregs and (D) MDSCs were quantitated by multiplying the number of CD45+ leukocytes by the percentage in each sample. The percentage of tumor-associated (E) Tregs and (F) MDSCs among CD45+ tumor leukocytes is shown. *p < 0.02, **p < 0.005, compared with VC. Data are derived from five mice per treatment group in two separate experiments.